Search

Series:

Clinical Minute Retina

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Show Description +

Which phase 3 data regarding faricimab (Vabysmo, Roche) should retina specialists keep in mind as the drug becomes available? On this debut episode of Clinical Minute: Retina, Ramin Tadayoni, MD, PhD, is joined by Charles Wykoff, MD, PhD, to review the latest clinical trial data linked to the first bispecific antibody indicated for ophthalmic use.

Posted: 4/06/2022

Keywords:

Clinical Trials

•

faricimab

•

vabysmo

•

Roche

•

bispecific

•

antibody

Up Next

Late-Presenting IOFBs: How To Detect Them—and Why They Are Missed

Late-Presenting IOFBs: How To Detect Them—and Why They Are Missed

Maria Berrocal, MD and Nimesh Patel, MD

AI Chatbots vs. Ophthalmology Trainees for Diagnosing and Triaging Common Conditions

AI Chatbots vs. Ophthalmology Trainees for Diagnosing and Triaging Common Conditions

Maria H. Berrocal, MD and Sruthi Arepalli, MD

Growing Comfortable with the Suprachoroidal Space

Growing Comfortable with the Suprachoroidal Space

Maria Berrocal, MD, and Robert L. Avery, MD

Update on Predatory Cell Therapy Clinics

Update on Predatory "Cell Therapy" Clinics

María H. Berrocal, MD and Ajay Kuriyan, MD

Is Teleretinal Screening for DR and DME Effective?

Is Teleretinal Screening for DR and DME Effective?

María H. Berrocal, MD; and Christina Y. Weng, MD, MBA

Drs. Berrocal and Chaudhry discuss the limitations of meta-analysis in ophthalmology research.

Drs. Berrocal and Chaudhry discuss the limitations of meta-analysis in ophthalmology research.

Maria Berrocal, MD, and Varun Chaudhry, MD

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Maria Berrocal, MD, and Usha Chakravarthy, MD, PhD

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Paulo E. Stanga, MD, and Maria H. Berrocal, MD

Clinical Minute: Retina: AI in ROP

Clinical Minute: Retina: AI in ROP

María Berrocal, MD and Darius Moshfeghi, MD

Clinical Minute: Retina: The Mac Tel Project

Clinical Minute: Retina: The Mac Tel Project

María Berrocal, MD and Lihteh Wu, MD

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Dante Pieramici, MD and María Berrocal, MD

Clinical Minute Retina: PPV for VH Secondary to RVO

Clinical Minute Retina: PPV for VH Secondary to RVO

Ramin Tadayoni, MD, PhD and Carl Regillo, MD

GATHER2 Data at 1 and 2 Years

GATHER2 Data at 1 and 2 Years

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Diana Do, MD, and Ramin Tadayoni, MD, PhD

Baseline Characteristics and Response to Intravitreal Dexamethasone Implant in DME

Baseline Characteristics and Response to Intravitreal Dexamethasone Implant in DME

Patricia Udaondo, MD, PhD and Ramin Tadayoni, MD, PhD

Biosimilars in Retina

Biosimilars in Retina

Ramin Tadayoni, MD, PhD, and Prof. Frank Holz

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Ramin Tadayoni, MD, PhD and Jean-Francois Korobelnik, MD, PhD

PPV vs Conventional Therapy for PDR

PPV vs Conventional Therapy for PDR

María H. Berrocal, MD, and Ramin Tadayoni, MD, PhD

ALOFT Study: Value of False Positive Alerts in Home Monitoring for Wet AMD Conversion

ALOFT Study: Value of False Positive Alerts in Home Monitoring for Wet AMD Conversion

Ramin Tadayoni, MD, PhD, and Allen C. Ho, MD

GA Therapy After the Newest DERBY/OAKS Data

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Protocol AC: Step Therapy in DME

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

TRUCKEE Study Data

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Pegcetacoplan Phase 3 Data

Pegcetacoplan Phase 3 Data

Ramin Tadayoni, MD, PhD and Caroline Baumal, MD

Rates of Endophthalmitis in a Nationwide Study

Rates of Endophthalmitis in a Nationwide Study

Ramin Tadayoni, MD, PhD; and Catherine Creuzot-Garcher, MD

Why Some Clinical Trials Succeed Where Others Do Not

Why Some Clinical Trials Succeed Where Others Do Not

Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD

AI in Retinal Imaging

AI in Retinal Imaging

Ramin Tadayoni, MD, PhD; Ursula Schmidt-Erfurth, MD

Intraoperative OCT: From Concept to Execution

Intraoperative OCT: From Concept to Execution

Ramin Tadayoni, MD, PhD; and Cynthia Toth, MD

AI in the Modern Age of Retina

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

The History of ILM Staining

The History of ILM Staining

Ramin Tadayoni MD, PhD; and Kazuaki Kadonosono, MD, PhD

Phase 3 Faricimab Data and the Dawn of a New Molecule

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Back to All Videos

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Which phase 3 data regarding faricimab (Vabysmo, Roche) should retina specialists keep in mind as the drug becomes available? On this debut episode of Clinical Minute: Retina, Ramin Tadayoni, MD, PhD, is joined by Charles Wykoff, MD, PhD, to review the latest clinical trial data linked to the first bispecific antibody indicated for ophthalmic use.

Posted: 4/06/2022

Keywords:

Clinical Trials

•

faricimab

•

vabysmo

•

Roche

•

bispecific

•

antibody

Please log in to leave a comment.

Comments

Tarik Saddik

3 years ago

What are those rocks behind him ?